BrainsWay (NASDAQ:BWAY – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $10.89 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
BrainsWay Stock Down 2.2 %
NASDAQ BWAY opened at $9.34 on Tuesday. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.79. The company has a market cap of $175.74 million, a price-to-earnings ratio of 93.41 and a beta of 1.25. The business’s fifty day moving average is $10.21 and its 200 day moving average is $9.52.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a report on Monday, December 23rd.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Stories
- Five stocks we like better than BrainsWay
- Why Are Stock Sectors Important to Successful Investing?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- 3 Dividend Kings To Consider
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
